Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date of Report: April 21, 2026
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Offering Price: $92.00 per share.
- Firm Shares Sold: 3,532,609 shares.
- Option Shares Exercised: 529,891 shares (underwriters exercised the 30-day option in full on April 22, 2026).
- Total Shares Sold: 4,062,500 shares.
- Estimated Net Proceeds: Approximately $350.9 million (after underwriting discounts, commissions, and estimated offering expenses).
- Underwriters: Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co.
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt levels. These operational metrics are not disclosed in this specific 8-K report.
Material Changes
The primary material change is the significant increase in the Company's cash liquidity through the issuance of new equity. The Company moved from a pre-offering state to having secured approximately $350.9 million in net proceeds, subject to closing conditions expected to be met on April 23, 2026.
Guidance, Outlook, and Risks
Management Commentary: The Company utilized a shelf registration statement (Form S-3ASR) filed on November 12, 2025, to execute this offering. The full text of the press release regarding the pricing is incorporated by reference.
Risks and Contingencies: The filing contains standard forward-looking statements regarding future events, noting that actual results may differ materially due to inherent risks and uncertainties. The Company explicitly states it does not assume an obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final closing of the offering on or after April 23, 2026.
- Confirm the exact net proceeds received after final deduction of all offering expenses.
- Review the Company's most recent 10-K or 10-Q for current cash balances, burn rate, and debt obligations to assess the impact of the new capital.
- Check for any dilution impact on existing shareholders given the issuance of 4,062,500 new shares.